Table 2.
Risk of sequential acquisition of cervical and anal HPV infection.
| HPV infectiona at the index site |
Prior HPV infectionb at the reference site |
Cervical (reference) HPV followed by anal (index) HPV |
Anal (reference) HPV followed by cervical (index) HPV |
Risk of anal HPV followed by cervical as compared to cervical HPV followed by anal |
||||
|---|---|---|---|---|---|---|---|---|
| Subjectsc (N= 751) |
Eventsd N |
Hazard Ratioe (95% CI)f |
Subjectsc (N= 751) |
Eventsd N |
Hazard Ratioe (95% CI)f |
Hazard Ratioe (95% CI)f |
||
| Any HPV type | none | 124 | 284 | 1.00 | 156 | 342 | 1.00 | |
| Any HPV type | Any HPV type | 75 | 99 | 20.5 (16.3-25.7) | 29 | 40 | 8.83 (6.36-12.2) | 0.55 (0.38-0.81) |
| HR-HPV | none | 83 | 114 | 1.00 | 95 | 145 | 1.00 | |
| HR-HPV | HR-HPV | 34 | 40 | 14.2 (9.86-20.5) | 12 | 13 | 7.08 (3.94-12.7) | 0.53 (0.28-1.00) |
| LR-HPVg | none | 103 | 170 | 1.00 | 122 | 197 | 1.00 | |
| LR-HPVg | LR-HPVg | 52 | 59 | 27.3 (20.4-36.7) | 22 | 27 | 10.1 (6.79-14.9) | 0.53 (0.33-0.85) |
| Alpha-1,8,10 | none | 29 | 31 | 1.00 | 33 | 36 | 1.00 | |
| Alpha-1,8,10 | Alpha-1,8,10 | 15 | 15 | 39.7 (21.0-75.1) | 4 | 5 | 8.62 (3.83-19.4) | 0.31 (0.13-0.78) |
| Alpha-3,15 | none | 64 | 78 | 1.00 | 76 | 93 | 1.00 | |
| Alpha-3,15 | Alpha-3,15 | 23 | 24 | 25.6 (16.2-40.4) | 12 | 13 | 9.09 (5.05-16.4) | 0.43 (0.22-0.86) |
| Alpha-5,6 | none | 50 | 55 | 1.00 | 48 | 62 | 1.00 | |
| Alpha-5,6 | Alpha-5,6 | 21 | 21 | 17.3 (10.5-28.6) | 5 | 5 | 4.89 (1.97-12.2) | 0.34 (0.14-0.85) |
| Alpha-7 | none | 44 | 53 | 1.00 | 50 | 58 | 1.00 | |
| Alpha-7 | Alpha-7 | 14 | 15 | 22.7 (12.7-40.6) | 5 | 5 | 6.84 (2.67-17.5) | 0.38 (0.14-1.09) |
| Alpha-9,11 | none | 44 | 56 | 1.00 | 62 | 77 | 1.00 | |
| Alpha-9,11 | Alpha-9,11 | 22 | 23 | 17.2 (10.5-28.0) | 5 | 7 | 12.9 (5.88-28.2) | 0.99 (0.38-2.56) |
| HPV-16 | none | 15 | 15 | 1.00 | 16 | 16 | 1.00 | |
| HPV-16 | HPV-16 | 9 | 9 | 9.03 (3.89-21.0) | 2 | 2 | 5.02 (1.08-23.2) | 0.58 (0.08-4.47) |
| HPV-18 | none | 14 | 14 | 1.00 | 9 | 9 | 1.00 | |
| HPV-18 | HPV-18 | 4 | 4 | 34.8 (9.69-124) | 1 | 1 | 9.25 (0.81-106) | 4.51 (0.25-80.6) |
| HPV-52 | none | 10 | 10 | 1.00 | 21 | 21 | ||
| HPV-52 | HPV-52 | 7 | 7 | 9.17 (3.67-23.0) | 0 | 0 | ||
| HPV-53 | none | 19 | 19 | 1.00 | 18 | 18 | 1.00 | |
| HPV-53 | HPV-53 | 10 | 10 | 16.8 (8.29-34.0) | 1 | 1 | 2.60 (0.39-17.5) | 0.13 (0.04-0.43) |
| HPV-84 | none | 23 | 23 | 1.00 | 19 | 19 | 1.00 | |
| HPV-84 | HPV-84 | 7 | 7 | 10.6 (4.62-24.1) | 2 | 2 | 4.17 (0.94-18.5) | 0.53 (0.09-3.16) |
| Comparison of sequential acquisition risk between genotype groups: | ||||||||
| LR-HPVg | LR-HPVg | 41 | 59 | 1.00 | 17 | 27 | 1.00 | |
| HR-HPV | HR-HPV | 34 | 40 | 0.58 (0.39-0.86) | 12 | 13 | 0.88 (0.46-1.69) | |
| Alpha-9,11 | Alpha-9,11 | 21 | 23 | 1.00 | 5 | 7 | 1.00 | |
| Alpha-1,8,10 | Alpha-1,8,10 | 15 | 15 | 2.91 (1.57-5.41) | 4 | 5 | 0.51 (0.19-1.42) | |
| Alpha-3,15 | Alpha-3,15 | 23 | 24 | 2.37 (1.34-4.19) | 12 | 13 | 0.93 (0.39-2.27) | |
| Alpha-5,6 | Alpha-5,6 | 21 | 21 | 1.61 (0.91-2.85) | 5 | 5 | 0.52 (0.16-1.76) | |
| Alpha-7 | Alpha-7 | 14 | 15 | 1.77 (0.93-3.34) | 5 | 5 | 0.56 (0.18-1.74) | |
| HPV-16 | HPV-16 | 9 | 9 | 1.00 | 2 | 2 | 1.00 | |
| HPV-18 | HPV-18 | 4 | 4 | 2.30 (0.71-7.40) | 1 | 1 | 7.19 (0.17-312 ) | |
| HPV-52 | HPV-52 | 7 | 7 | 0.89 (0.36-2.21) | 0 | 0 | ||
| HPV-53 | HPV-53 | 10 | 10 | 2.94 (1.16-7.47) | 1 | 1 | 0.17 (0.04-0.75) | |
| HPV-84 | HPV-84 | 7 | 7 | 1.75 (0.66-4.67) | 2 | 2 | 1.26 (0.20-7.98) | |
Incident (detected at a visit other than the first) HPV infection at the index site.
Infection with the same genotype as the index HPV infection. For example, for index HR-HPV and reference HR-HPV, only those are included who had HPV-16 in the cervix and HPV-16 in the anus, HPV-18 in the cervix and HPV-18 in the anus, etc.
The number of subjects who completed the questionnaire and at least 2 clinical visits.
The number of incident HPV infections at the index site after same-type HPV infections at the reference site during the study period.
Adjusted for age of participants at study entry.
CI, confidence interval.
Includes undetermined-risk HPV types.
Note: α-Papillomavirus species; species 1 comprises types 42 and 89; species 3 comprises types 61, 62, 81, 83, and 84; species 5 comprises types 51 and 82; species 6 comprises types 53, 56, and 66; species 7 comprises types 18, 39, 45, 59, 68, and 70; species 9 comprises types 16, 31, 33, 35, 52, 58, and 67; and species 10 comprises types 6, 11, and 44.